Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtech Start-Up Financing Strategies: Where’s The Money?

This article was originally published in Start Up

Executive Summary

Despite the dire headlines, VCs are still investing in medtech start-ups, although the deals are becoming fewer and later stage. Start-ups looking for funding have to be more creative and look beyond traditional sources of funding, according to a discussion by six European venture capitalists speaking at the IN3 meeting in Dublin in April 2013.

You may also be interested in...

EIF Putting Euros To Work In European VCs, Angels

With €12 billion under management, the European Investment Fund has made a significant imprint on Europe’s venture capital community. The EIF holds stakes in more than 260 venture capital funds in Europe and is invested in roughly 80% of the active European VC funds.

Overcoming The Bias Against Medtech Entrepreneurship In Europe: An Interview With Martin Rothman

Why are European physicians so far ahead of the curve when it comes to innovative clinical practice and so far behind when it comes to creating companies? Interventional cardiologist and serial entrepreneur Martin Rothman offers some answers.

Device Investors Showing Some Spine

Elsevier’s Strategic Transactions shows that just in the last year, 26 spine or low back pain companies received private funding. To be sure, many were small rounds, some were funded with debt, and some were insider rounds trying to keep companies moving forward, but venture investors showed excitement by investing in large rounds for a select number of start-ups.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts